Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Carl R. who wrote (2070)	1/26/2000 12:26:00 PM
From: pz	Respond to of 5582

Carl, I take Zicam twice a day and don't find it unpleasant at all to use. The first time I took Zicam was when I had a cold with a sore throat. I did have a very slight burning sensation, but I think that was due to my raw throat. Like I say, I take it twice a day as a preventative now, and haven't experience the burning sensation since. It's just part of my daily routine. Also I haven't had a cold or flu since I've started using Zicam daily, where most of the people where I work have been sick. Paul

To: Carl R. who wrote (2070)	1/26/2000 1:11:00 PM
From: Ron S	Read Replies (1) \| Respond to of 5582

January is prediction time, so scoping some news items over the next six months: Feb: GUMM announces Giant 4Q Revenue Gains with First Net Profit. 2nd Clinicals Released & Confirms 1st and More Newsweak does Cover/feature Article on Zicam Mar: Morgate Lynch Initiates Coverage - Strong Buy, $75 target Zicam Production Boosted Again IBDoily New America page Devoted to Gum Tech Apr: GUMM noted to be #1 performing NASDQ stock in 2000's 1Q Salmon Sachs Starts Coverage with $100 Target Advertising Begins as Production almost Catches up to Demand May: New Dental Gum Introduced by Wralgey/Gum Tech JV SwedMatch Blankets Europe with Anti-Cigarette Gum Campaign GUMM Announces New Gel Delivery Products for Flu and Asthma Jun: WSJ says End of Cold/Flu Season Drops Related Sales, but Gum Tech says June Zicam Sales Running Triple the 1st Quarter GUMM's Buyout of Other 40% of Zicam for $200 mil to be Accretive. Jul: Fidelijanis Reveals it Bought Millions of GUMM shares in 1st Half Glaxvartis to Roll Out Zicam in Europe in Partnership with GUMM. Zicam Sales in Southern Foreign Winter Climates Exceeding U.S. And, finally, GUMM management terms BristleBayr $200 per Share Offer not reflective of its real value.